Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mono- and Bispecific human antibodies

            Therapeutic Area: Oncology Product Name: OmniAb

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

            Deal Size: $5.0 million Upfront Cash: $5.0 million

            Deal Type: Acquisition September 14, 2020

            Details:

            The acquisitions are expected to enable Ligand to secure new license agreements with expanded economics as a result of the addition of tools and intellectual property that Ligand can now offer to partners.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mono- and Bispecific human antibodies

            Therapeutic Area: Oncology Product Name: OmniAb

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

            Deal Size: $7.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition September 10, 2020

            Details:

            The acquisition will strengthen company's OmniAb® technology platform. Potential for two approvals of OmniAb-derived antibodies in 2021 with expected new royalty streams to Ligand.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $85.0 million Upfront Cash: Undisclosed

            Deal Type: Financing July 29, 2020

            Details:

            Financing proceeds support identification of novel therapeutic targets and enable genomic medicine programs across a wide range of therapeutic areas

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV-based gene therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Daiichi Sankyo Co Ltd

            Deal Size: $225.0 million Upfront Cash: $125.0 million

            Deal Type: Licensing Agreement April 01, 2020

            Details:

            Ultragenyx granted Daiichi Sankyo license to intellectual property, including know-how and patent applications, with respect to its HeLa manufacturing platform for AAV-based gene therapy products.